Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 is a unique technology that enables the geneticists and medical researchers to edit parts of the genome by removing, adding or altering sections of the deoxyribonucleic acids (DNA) sequence. The CRISPR-Cas9 system consists of two key molecules that introduce a mutation into the DNA. The first component is an enzyme, which is called as Cas9. This acts as a pair of ‘molecular scissors’ that can cut the two strands of DNA at a specific location in the genome so that bits of DNA can then be added or removed. The second component is called guide RNA (gRNA). This consists of a small piece of pre-designed RNA sequence (about 20 bases long) located within a longer RNA scaffold. The scaffold part binds to DNA and the pre-designed sequence ‘guides’ Cas9 to the right part of the genome. This makes sure that the Cas9 enzyme cuts at the right point in the genome.

Market Dynamics

Key players are developing various treatment options, such as CRISPR and CAS genes, for genetic diseases. For instance, in 2016, the U.S.-based company, Addgene, developed the KamiCas9, a version of CRISPR-Cas9 that includes a 'self-inactivating' KamiCas9 system for the editing of central nervous system (CNS) disease genes for the treatment of Huntington’s disease.

CRISPR technology is widely used to develop therapeutics for diseases such as diabetes, cancer, etc. Hence, the increasing prevalence of such diseases is expected to drive the market growth over the forecast period. According to The International Diabetes Federation, in 2019, approximately 463 million adults (20-79 years of age) were living with diabetes; by 2045, this will increase to 700 million worldwide. Moreover, one in five of the people who are above 65 years old have diabetes.

Furthermore, according to data findings by the World Health Organization (WHO), in February 2018, cancer was the second-leading cause of death globally, and around 18.1 million new cases and 9.6 million deaths were registered due to cancer. According to the same source, around 70% of deaths from cancer occurred in low and middle income countries, and around one in six deaths across the globe were caused by cancer.

 Key features of the study:

• This report provides an in-depth analysis of global CRISPR and CAS gene market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global CRISPR and CAS gene market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Merck KGaA (Sigma-Aldrich), OriGene Technologies, Inc., New England Biolabs, Cellecta, Inc., Agilent Technologies, Inc., Applied StemCell, Inc., Synthego, Genscript, Mirus Bio LLC, Integrated DNA Technologies, Inc., and Mammoth Biosciences, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global CRISPR and CAS gene market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the CRISPR and CAS gene market

Detailed Segmentation:

• Global CRISPR and CAS Gene Market, By Product Type:
  • Vector-based CAS
  • DNA-free CAS
  • Others
• Global CRISPR and CAS Gene Market, By Application:
  • Genome Engineering
  • Disease Models
  • Functional Genomics
  • Knockdown/Activation
  • Others
• Global CRISPR and CAS Gene Market, By End User:
  • Biotechnology and Pharmaceutical Companies
  • Academic & Government Research Institutes
  • Contract Research Organizations
• Global CRISPR and CAS Gene Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country:
      • U.K.
      • Germany
      • Italy
      • Spain
      • France
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • Australia
      • India
      • China
      • Japan
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Thermo Fisher Scientific Inc. *
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Merck KGaA (Sigma-Aldrich)
  • OriGene Technologies, Inc.
  • New England Biolabs
  • Cellecta, Inc.
  • Agilent Technologies, Inc.
  • Applied StemCell, Inc.
  • Synthego
  • Genscript
  • Mirus Bio LLC
  • Integrated DNA Technologies, Inc.
  • Mammoth Biosciences, Inc.

“*” marked represents similar segmentation in other categories in the respective section.